

Ref. No.: NLL/CS/2026- 661

March 06, 2026

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub: Update on Acquisition of 100% paid- up equity share capital of Avenis Exports Private Limited (CIN: U51109DL2007PTC169484) ("AEPL")

Ref.: Regulation 30 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

Dear Sir/ Madam,

This is with reference of disclosures by Nectar Lifesciences Limited ("Company") as per point no. 1 of its letter no. NLL/CS/2026- 659 dated March 02, 2026 and Annexure A thereto as required under LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

This is to inform you that on March 06, 2026, the Company concluded the acquisition of the entire paid- up equity share capital in AEPL. The acquisition was made for a total cash consideration of INR 24,96,000/- and paid through normal banking channels.

Following this transfer of shares from existing holders, AEPL has become a Wholly Owned Subsidiary of the Company with effect from March 06, 2026.

Please treat this disclosure as a forms and part of Annexure A of Company's letter no. NLL/CS/2026- 659 dated March 02, 2026.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer